Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma Patients.

Authors

Claudio Favre, Gianluca Mattei, Cristina Banella, Amada Pasha, Stefania Crucitta, Gennaro Bruno, Rachele Amato, Camilla Rosa, Alessandro Pini, Patrizia Nardini, Federica Lunardi, Federica Carra, Francesca Trevisan, Emanuela De Marco, Marco Tellini, Irene Trambusti, Maria Vittoria Micheletti, Francesco Pasqualetti, Gabriella Casazza, Annalisa Tondo, Maura Calvani

Published in

FASEB journal : official publication of the Federation of American Societies for Experimental Biology. Volume 40. Issue 14. Pages e71920. Jul 31, 2026.

Abstract

Neuroblastoma (NB) remains a challenge due to the lack of robust prognostic biomarkers for risk stratification and treatment guidance. The β3-adrenergic receptor (β3-AR) is implicated in tumor progression and metastasis. The present study evaluates the detection of β3-AR in different tissues and its correlation with survival and clinical characteristics of NB patients. β3-AR expression was analyzed in bone marrow (BM), peripheral blood (PB), circulating tumor cells (CTCs), disseminated tumor cells (DTCs), and tumor biopsies by flow cytometric analysis and immunofluorescence. Receiver Operating Characteristic (ROC) curves, Fisher's exact test, and Kaplan-Meier curves were used to investigate the validity of β3-AR as a prognostic marker. Statistical analyses were performed by R software and MedCalc. In our cohort of 45 NB patients, β3-AR expression in PB was significantly higher compared to healthy controls (p = 1.839e-07 at diagnosis; p = 0.0006 at follow-up, p < 0.001) and showed strong correlation across tissues (r > 0.72). High β3-AR expression in DTCs at diagnosis (≥ 96.5%) was associated with shorter event-free survival (p = 0.0005). Elevated β3-AR in BM at diagnosis predicted worse overall survival (p = 0.0076). At follow-up, increased β3-AR expression in PB correlated with shorter overall survival (27 months vs. not reached, p = 0.0015). These findings highlight β3-AR as a promising prognostic biomarker for NB risk stratification and disease progression.

PMID:
42455511
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.